Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi
Phase 2
Recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed Tomography
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 30
- Registration Number
- NCT06466122
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Phase 2
Withdrawn
- Conditions
- Chronic Lymphocytic LeukemiaLoss of Chromosome 17p
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Kerry Rogers
- Registration Number
- NCT03943342
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Phase 1
Active, not recruiting
- Conditions
- Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Drug: Bcl-2 Inhibitor GDC-0199Biological: ObinutuzumabOther: Pharmacological StudyOther: Laboratory Biomarker AnalysisOther: Quality-of-Life Assessment
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 87
- Registration Number
- NCT02427451
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath